Aggrenox

cardiac valve replacement, Ischemic Attack, Transient, Coronary Disease + 9 more
Treatment
6 FDA approvals
12 Active Studies for Aggrenox

What is Aggrenox

DipyridamoleThe Generic name of this drug
Treatment SummaryDipyridamole is a medication that blocks the absorption and breakdown of adenosine in red blood cells and in the cells that line blood vessels. It also makes prostacyclin, a drug that stops blood clots, work better.
Dipyridamoleis the brand name
Aggrenox Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dipyridamole
Dipyridamole
1980
98

Approved as Treatment by the FDA

Dipyridamole, also known as Dipyridamole, is approved by the FDA for 6 uses like Postoperative Thromboembolism and cardiac valve replacement .
Postoperative Thromboembolism
cardiac valve replacement
Venous Thrombosis
Stroke
Used to treat Cerebrovascular Accident in combination with Acetylsalicylic acid
Stroke
Used to treat previous stroke in combination with Acetylsalicylic acid
Transient Ischemic Attack (TIA)
Used to treat Transient Ischemic Attack in combination with Acetylsalicylic acid

Effectiveness

How Aggrenox Affects PatientsDipyridamole is a medicine used to widen the blood vessels, stop blood clots, and help prevent stroke. It is usually taken together with other anticoagulant drugs such as warfarin to prevent blood clots in patients with valve or vessel problems. It can also be used to take pictures of the heart, stop platelets from sticking together, and used with aspirin to lower the risk of stroke.
How Aggrenox works in the bodyDipyridamole works to stop platelets from clumping together and forming clots by preventing the breakdown of compounds that inhibit platelet function. It also increases the amount of a compound in the platelets that stops them from sticking together. Finally, Dipyridamole directly triggers the release of another compound which further raises the amount of the inhibitor compound inside the platelets.

When to interrupt dosage

The proposed portion of Aggrenox is contingent upon the diagnosed condition, such as Thrombosis, previous stroke and Stroke. The amount of dosage will depend on the technique for delivery (e.g. Tablet, coated or Capsule) highlighted in the table hereunder.
Condition
Dosage
Administration
cardiac valve replacement
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Ischemic Attack, Transient
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Coronary Disease
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Stroke
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Heart Valve Prosthesis
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Myocardial Perfusion Imaging
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Venous Thrombosis
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Anti-platelet Therapy
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Ischemic Stroke
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Stroke
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Diagnostic Imaging
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release
Transient Ischemic Attack (TIA)
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
Tablet - Oral, Tablet, Capsule, Oral, Capsule - Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Injection - Intravenous, Injection, Intravenous, Solution - Intravenous, Solution, Injection, solution, Injection, solution - Intravenous, Liquid - Intravenous, Liquid, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release - Oral, Tablet, extended release

Warnings

Aggrenox Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Atrioventricular Block
Do Not Combine
Respiratory Sounds
Do Not Combine
There are 20 known major drug interactions with Aggrenox.
Common Aggrenox Drug Interactions
Drug Name
Risk Level
Description
Abrocitinib
Major
The risk or severity of bleeding and thrombocytopenia can be increased when Dipyridamole is combined with Abrocitinib.
Acebutolol
Major
Dipyridamole may increase the bradycardic activities of Acebutolol.
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Dipyridamole.
Alprenolol
Major
Dipyridamole may increase the bradycardic activities of Alprenolol.
Alprostadil
Major
The risk or severity of hypotension and priapism can be increased when Dipyridamole is combined with Alprostadil.
Aggrenox Toxicity & Overdose RiskLow blood pressure may be a short-term side effect of this drug, but a medication to raise blood pressure may be prescribed if needed. The lowest toxic dose in rats was found to be greater than 6,000 mg/kg, while in dogs it was approximately 400 mg/kg. The lethal dose in rats is 8.4g/kg when taken orally.

Aggrenox Novel Uses: Which Conditions Have a Clinical Trial Featuring Aggrenox?

38 active trials are being conducted to assess the potential of Aggrenox in Postoperative Thromboembolism, Stroke and Thrombotic Disorders management.
Condition
Clinical Trials
Trial Phases
Coronary Disease
1 Actively Recruiting
Not Applicable
Venous Thrombosis
0 Actively Recruiting
cardiac valve replacement
0 Actively Recruiting
Heart Valve Prosthesis
0 Actively Recruiting
Transient Ischemic Attack (TIA)
2 Actively Recruiting
Phase 4, Not Applicable
Diagnostic Imaging
0 Actively Recruiting
Ischemic Stroke
2 Actively Recruiting
Not Applicable
Ischemic Attack, Transient
0 Actively Recruiting
Anti-platelet Therapy
0 Actively Recruiting
Stroke
0 Actively Recruiting
Stroke
6 Actively Recruiting
Not Applicable, Phase 1
Myocardial Perfusion Imaging
1 Actively Recruiting
Phase 1

Aggrenox Reviews: What are patients saying about Aggrenox?

5Patient Review
10/14/2016
Aggrenox for Prevention of Blood Clots in the Brain
I had a TIA three years ago and was put on Clopidogrel. However, I developed mild numbness in my face after just fifteen days. So, I changed neurologists and he suggested Aggrenox. I had a headache for the first two days but then nothing else. I continued taking Aggrenox and now it's been three years with no further TIAs or side effects (besides mild acidity).
5Patient Review
7/30/2013
Aggrenox for Prevention of Blood Clots in the Brain
My doctor prescribed this in order to lower my HDL levels. It was successful, and I experienced some side effects; however, they eventually went away with continued use of the drug.
5Patient Review
1/9/2014
Aggrenox for Prevention of Blood Clots in the Brain
I had an ischemic stroke when I was 51, and Aggrenox has been a lifesaver. Not only have I not had any more strokes or TIA's, but I also haven't experienced any headaches. The only downside is that I sometimes bleed from my anus, but it's not too bad.
5Patient Review
1/27/2014
Aggrenox for Prevention of Blood Clots in the Brain
I've been on Aggrenox for six years now, and it has prevented any further mini-strokes (TSA) since I started taking it. I'm very pleased with the results and have experienced no negative side effects whatsoever.
5Patient Review
4/1/2013
Aggrenox for Prevention of Blood Clots in the Brain
4.3Patient Review
5/20/2014
Aggrenox for Prevention of Blood Clots in the Brain
I had two strokes in 2002 and my carotid artery was 100% blocked. I've been taking Aggrenox for 12 years now, and the only problem I've had was after 5 years when I started having stomach problems. I went on omeprazole and that fixed the issue. My only concern now is that I need knee replacement surgery and no orthopedic surgeons know anything about this drug or how long I can stop taking it for safety. Does anyone know the answer?
4.3Patient Review
11/30/2013
Aggrenox for Prevention of Blood Clots in the Brain
The side effects were unfortunately quite debilitating. I couldn't really function at all while taking this medication.
4Patient Review
6/17/2015
Aggrenox for Prevention of Blood Clots in the Brain
I've been taking aspirin for years per my doctor's recommendation, but recently he prescribed Aggrenox because I had a TIA about 10 years ago with no recurrence. I have met my donut hole, and the stuff costs a fortune. I've called the doc to find out if I can resume taking just aspirin, as I had for years. Before he gets back to me, can anyone tell me if they have noticed a perceptable difference between Aggrenox and 81 mg aspirin? Is it worth the outrageous price vs. $3 for a year's worth of aspirins?
2Patient Review
7/11/2014
Aggrenox for Prevention of Blood Clots in the Brain
I have found that Aggrenox has caused me to lose my appetite, constantly feel nauseous, and experience a bad taste in my mouth. I've also lost weight since taking this medication. I'm hoping to explore other options with my doctor soon.
1Patient Review
2/17/2015
Aggrenox for Prevention of Blood Clots in the Brain
My father experienced a brain embolism and was prescribed Aggrenox. One week later, he had a major cerebral bleed and died. This is not a good drug!
1Patient Review
9/5/2013
Aggrenox for Prevention of Blood Clots in the Brain
I've been taking this medication for 15 years with no problems. However, I have recently started experiencing pain and wonder if it would be okay to take Advil or Aleve

Patient Q&A Section about aggrenox

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Aggrenox the same as aspirin?

"Aggrenox consists of aspirin and dipyridamole, which is another medication. Those who have had a stroke or TIA in the past generally take either aspirin or Aggrenox, but not both."

Answered by AI

What is the generic name for Aggrenox?

"The FDA approved the generic version of Aggrenox, aspirin/extended-release dipyridamole, on July 1, 2015. This medication is used to help prevent stroke in people who have had a previous "mini-stroke" or an actual ischemic stroke."

Answered by AI

What is the difference between Aggrenox and Plavix?

"Plavix protects you from blood clots after you have had a heart attack or surgery. It is a cheap, generic drug that is just as effective as more expensive options. Aggrenox prevents blood clots and stroke, but there are cheaper drugs available that work just as well."

Answered by AI

What is the medication Aggrenox used for?

"This medication is mean to prevent another stroke from happening to patients who have already had mini strokes or a single full stroke. The medication works by thinning the blood so that clots are less likely to form and cause another stroke."

Answered by AI

Clinical Trials for Aggrenox

Image of University of Michigan in Ann Arbor, United States.

Brain Stimulation for Stroke and Aphasia

18+
All Sexes
Ann Arbor, MI
The goal of this clinical trial is to determine if electrical brain stimulation applied to the front parts of the brain can help people who have had a stroke improve their fatigue, language, and attention. The main question it aims to answer is: * Does transcranial direct current stimulation (tDCS) administered to the pre-frontal areas of the brain improve post-stroke fatigue and aphasia? * What kinds of participant characteristics are associated with better improvement of post-stroke fatigue and aphasia? Researchers will compare active electrical stimulation to sham stimulation to see if the active stimulation does a better job at reducing fatigue and language deficits after stroke. Participants will be asked to complete fatigue, language, and cognitive testing before and after receiving 10 sessions of tDCS plus speech and language therapy.
Recruiting
Device
University of Michigan (+1 Sites)
Image of Kessler Foundation in West Orange, United States.

Robotic Balance Training + Brain Stimulation for Stroke

18 - 75
All Sexes
West Orange, NJ
Our proposed study, "NEUROBALANCE Stroke,"; aims to evaluate the effectiveness of a combined intervention involving robotic balance training and noninvasive brain stimulation in improving balance function and postural control in individuals with chronic stroke. The study will recruit 45 participants who have had a stroke at least 6 months before enrolment and experience persistent balance and gait deficits. Participants will be randomized into three groups: (1) robotic balance training with active brain stimulation, (2) robotic balance training with sham brain stimulation, and (3) standard-of-care rehabilitation. The study will involve 15 training sessions over 5 weeks, with assessments conducted at baseline, post-training, and two months post-training to evaluate balance recovery and retention. The primary focus is understanding how this intervention affects brain and muscle activity during balance tasks and how these changes translate into functional improvements in clinical outcome measures of balance function. Additionally, participant feedback on brain stimulation and exercise engagement will be collected to inform future studies. The findings may guide the development of personalized training protocols and contribute to broader rehabilitation strategies.
Recruiting
Device
Kessler FoundationVikram Shenoy Handiru,, PhD
Image of Brooks Rehabilitation Clinical Research Center in Jacksonville, United States.

Q Therapeutic System for Stroke

18 - 80
All Sexes
Jacksonville, FL
This trial tests a promising new intervention to promote post-stroke neural reorganization and functional recovery. The Q Therapeutic (BQ 3.0) is a wearable medical system that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. This trial is a prospective, single-arm, open-label, single center clinical trial designed to evaluate the safety, feasibility, and efficacy of the Q Therapeutic (BQ 3.0) System in the rehabilitation of people with chronic stroke.
Recruiting
Has No Placebo
Brooks Rehabilitation Clinical Research CenterEmily Fox, PT, DPT, MHS, PhDBrainQ Technologies Ltd.
Have you considered Aggrenox clinical trials? We made a collection of clinical trials featuring Aggrenox, we think they might fit your search criteria.Go to Trials
Have you considered Aggrenox clinical trials? We made a collection of clinical trials featuring Aggrenox, we think they might fit your search criteria.Go to Trials
Image of National Institutes of Health Clinical Center in Bethesda, United States.

Low SAR MRI Scans for Coronary Heart Disease

18 - 100
All Sexes
Bethesda, MD
Background: Researchers are testing version of a system known as a magnetic resonance imagining (MRI) scanner that uses strong magnetic fields, radio waves and the like to create images of the organs in the body. It uses lower energy levels than other MRI scanners. This may help scan people with metal devices in their body, or in invasive heart procedures using metal tools. Objective: To test a new MRI scanner and software changes to create better pictures. Eligibility: People with disease and healthy volunteers, ages 18 and older. Design: Participants will be screened with blood tests. Participants may have both the new MRI and a conventional MRI or only the new one. If 2 are done, they must be within 60 days. For both MRI versions, participants lie on a table that slides into a large tube. During scans, they will hold their breath for up to 20 seconds at a time. Heart activity will be measured by wires connected to pads on the skin. A flexible belt may be used to monitor their breathing. They will be in the scanner up to 2 hours. Participants can agree to have a dye called gadolinium injected into their arm during the scan. This brightens the pictures. Participants can agree to take a drug called a vasodilator. This helps detect areas of the heart with abnormal blood supply. Scans of the heart are taken before, during, and after they get the medicine. The drug may cause temporary chest pain or shortness of breath. They may get other drugs to relieve these symptoms. Sponsoring Institution: National Heart, Lung, and Blood Institute
Recruiting
Has No Placebo
National Institutes of Health Clinical CenterAdrienne E Campbell, Ph.D.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security